Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 1
2004 1
2005 5
2006 4
2007 5
2008 6
2009 6
2010 15
2011 17
2012 18
2013 13
2014 15
2015 16
2016 17
2017 22
2018 42
2019 42
2020 45
2021 37
2022 37
2023 30
2024 22
2025 24
2026 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

396 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hong jae lee (91 results)?
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Olawaiye AB, et al. Among authors: lee yj. Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2. Lancet. 2025. PMID: 40473448 Clinical Trial.
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
Lorusso D, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Fagotti A, Gilbert L, Mileshkin L, Quesada S, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Clamp A, Prillaman C, Diakos C, Bagaméri A, Leiser AL, Salutari V, Monk BJ, Follana P, McClung E, Carbone V, Slomovitz B, Giudice E, Cannizzaro MC, Gavoille L, Devaux A, Scollo P, Scandurra G, Cassani C, Artioli G, Van Gorp T, Santaballa A, Dreiling LK, Kesner-Hays A, Tudor IC, Jubb AM, Colombo N, Olawaiye AB. Lorusso D, et al. Among authors: lee yj. Lancet. 2026 Apr 18;407(10538):1513-1524. doi: 10.1016/S0140-6736(26)00462-9. Epub 2026 Apr 10. Lancet. 2026. PMID: 41974149 Free article. Clinical Trial.
New markers in metabolic syndrome.
Son DH, Ha HS, Park HM, Kim HY, Lee YJ. Son DH, et al. Among authors: lee yj. Adv Clin Chem. 2022;110:37-71. doi: 10.1016/bs.acc.2022.06.002. Epub 2022 Jul 25. Adv Clin Chem. 2022. PMID: 36210076 Review.
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.
Ngoi NYL, Lee JY, Lim D, Thian YL, Lim YW, Chan JJ, Chay WY, Zhang Z, Gopinathan A, Lim SE, Low J, Ng J, Tong P, Lee YJ, Park J, Kim JW, Tan TZ, Zhu J, Tai BC, Choi CH, Kim BG, Tan DSP. Ngoi NYL, et al. Among authors: lee yj. Lancet Oncol. 2026 Feb;27(2):201-211. doi: 10.1016/S1470-2045(25)00662-X. Epub 2026 Jan 15. Lancet Oncol. 2026. PMID: 41548565 Clinical Trial.
Recent Advances in Anti-Aging Medicine.
Son DH, Park WJ, Lee YJ. Son DH, et al. Among authors: lee yj. Korean J Fam Med. 2019 Sep;40(5):289-296. doi: 10.4082/kjfm.19.0087. Epub 2019 Sep 20. Korean J Fam Med. 2019. PMID: 31558007 Free PMC article.
396 results